



# Relative hyperventilation in non-ventilated patients with spinal muscular atrophy

*To the Editor:*

Spinal muscular atrophy (SMA) is a relatively common autosomal recessive neuromuscular disorder, characterised by progressive degeneration of spinal cord and bulbar motor neurons. It is caused by survival motor neuron (SMN) protein deficiency, due to homozygous loss of function of the *SMN1* gene. Due to the effects of genetic modifiers, SMA displays a broad range in severity. The current clinical classification system distinguishes four types, based on age at onset and acquired motor milestones, *i.e.* infantile onset without achieving the ability to sit (type 1), childhood onset with the ability to sit but not to walk (type 2), childhood onset with the ability to walk for at least a short period of time (type 3) and adult onset with mild symptoms (type 4) [1, 2]. Disease course is progressive, irrespective of type [3] and patients with SMA type 1, 2 and 3 are at high or moderate risk of developing respiratory insufficiency, which may necessitate initiating mechanical ventilation [4, 5].

Reduced lung function in SMA is probably the most important cause of morbidity and mortality in patients with SMA [1, 6, 7] and is caused by a rather unique pattern of weakness that predominates in the intercostal muscles and relatively spares the diaphragm [8]. Both inefficient secretion clearance, leading to recurrent respiratory tract infections and lung damage, as well as hypoventilation, can occur from an early age [6, 9].

There is consensus that patients with SMA type 2 and 3 with symptomatic nocturnal hypoventilation or daytime hypercarbia should start home mechanical ventilation [6] to correct hypoventilation and associated symptoms [10]. In accordance with national guidelines, mechanical ventilation is initiated in our centre in cases of symptoms of nocturnal hypoventilation and a carbon dioxide tension ( $P_{CO_2}$ )  $\geq 45$  mmHg, or when  $P_{CO_2}$  increases to  $\geq 52.5$  mmHg without symptoms. Therefore, measurements of capillary  $P_{CO_2}$  during routine follow-up visits are used to screen for hypoventilation. In case of symptoms of nocturnal hypoventilation or increased daytime  $P_{CO_2}$ , overnight measurements are obtained to confirm or exclude nocturnal hypoventilation.

In daily practice we noticed that  $P_{CO_2}$  levels are regularly lowered or within the lower range of normal, rather than increased, in patients with SMA without ventilatory support. Therefore, we retrospectively analysed capillary  $P_{CO_2}$  levels. We only used samples from patients who were not mechanically ventilated at the time of sample collection. Blood samples were obtained during visits to our outpatient clinic. Measurements obtained during hospital admissions or emergency department visits were excluded.

We assessed longitudinal changes of  $P_{CO_2}$  levels in non-ventilated patients with a linear mixed-effects model, which included a random intercept and random slope for time per individual. We accounted for the non-linear increase in  $P_{CO_2}$  by modelling the fixed effect of time as a cubic function. Confidence intervals were estimated using bootstrapping ( $n=1000$ ) and significance tests were based on the likelihood ratio test. This study was approved by the local medical ethics committee. Informed consent was obtained from all participants and/or their parents in case of minors.

 @ERSpublications

**Lower ranges of carbon dioxide levels are normal in non-ventilated SMA patients. Physicians should be aware of pending respiratory insufficiency if carbon dioxide levels increase to normal levels in patients with pre-existing low carbon dioxide levels** <https://bit.ly/2Ag7jQ5>

**Cite this article as:** Veldhoen ES, Wijngaarde CA, Verweij-van den Oudenrijn LP, *et al.* Relative hyperventilation in non-ventilated patients with spinal muscular atrophy. *Eur Respir J* 2020; 56: 2000162 [<https://doi.org/10.1183/13993003.00162-2020>].

We analysed 708 capillary blood samples from 69 patients with genetically confirmed SMA. The median (interquartile range (IQR)) number of samples per patients was nine (4–14) with a median (IQR) 9 (3–13) years follow-up. Median (IQR) age at sample collection was 16.2 (10.6–28.4) years. The majority of patients had SMA type 2 (n=52, 75%), and the remainder had type 3 (n=14, 20%) or type 1 (n=3, 4%). Mean  $P_{\text{CO}_2}$  was 35.5 mmHg (95% CI 34.7–36.2 mmHg; reference range of 35–45 mmHg) (figure 1a). Lowered  $P_{\text{CO}_2}$  levels were not the result of concomitant metabolic acidosis, as mean pH was 7.44 (95% CI 7.43–7.44) and mean bicarbonate level was 23.6 mmol·L<sup>-1</sup> (95% CI 23.3–24.1 mmol·L<sup>-1</sup>; reference range 22.0–29.0 mmol·L<sup>-1</sup>).

At the time of writing, 48 (70%) patients did not require (non-)invasive ventilation, whereas in the other 21 patients (non-)invasive ventilation was initiated. Eight (38%) patients could not be weaned off mechanical ventilation after an episode of acute respiratory failure due to infection (n=7) or surgery (n=1); the other 13 (62%) developed nocturnal hypoventilation. Median (IQR) age at initiation of ventilation for these 21 patients was 18.5 (11.4–37.0) years.

As all samples were taken prior to initiating (non-)invasive ventilation, we compared blood  $P_{\text{CO}_2}$  levels over time between the two groups. Levels of  $P_{\text{CO}_2}$  were lowered or within the lower range of normal in blood samples of the 48 patients in whom mechanical ventilation had not been initiated (mean  $P_{\text{CO}_2}$  35.4 mmHg, 95% CI 34.5–36.3 mmHg; n=192). Similar results were found for the 21 patients who ultimately required ventilation, in their samples obtained >1 year prior to start of (non-)invasive mechanical ventilation. However, a significant increase in  $P_{\text{CO}_2}$  levels was observed in the year prior to initiation of mechanical ventilation (figure 1b): 5 years prior to initiation of ventilation mean daytime capillary  $P_{\text{CO}_2}$  was 34.2 mmHg (95% CI 32.9–35.3 mmHg; n=21), increasing to 36.7 mmHg (95% CI 35.2–38.1 mmHg) 1 year prior to start of mechanical ventilation (p<0.001) and further to 37.8 mmHg (95% CI 36.2–39.5 mmHg) at the start of mechanical ventilation.

Together, these data show that most non-ventilated patients with SMA have daytime  $P_{\text{CO}_2}$  levels in the lower range of normal. These levels increase to or beyond the upper limit of normal in the year prior to initiation of (non-)invasive ventilation. Additionally, overnight  $P_{\text{CO}_2}$  levels in non-ventilated patients show similar results. Mean overnight arterial  $P_{\text{CO}_2}$  (187 measurements, 34 patients) was 36.1 mmHg (95% CI 35.0–37.2 mmHg). In patients who ultimately required (non-)invasive ventilation (n=16), there was a significant increase of 0.38 mmHg per year (95% CI 0.08–0.86 mmHg; p=0.013), whereas it remained stable in patients not requiring ventilation (n=18).




FIGURE 1 Capillary carbon dioxide tension [ $P_{\text{CO}_2}$ ] in a) all patients at different ages and b) patients who ultimately required ventilation, at time before initiation of ventilation. Horizontal lines represent normal range of carbon dioxide levels (35–45 mmHg). Regression line:  $P_{\text{CO}_2} = 38.0 + (1.272 \times \text{time}) + (0.126 \times \text{time}^2) + (0.004 \times \text{time}^3)$ .

Levels of  $P_{CO_2}$  in SMA have been studied previously by KHIRANI *et al.* [11]. They reported  $P_{CO_2}$  levels within normal range in 16 SMA patients and slight increase with age in patients with SMA type 2. Although mean values were not specified, their published longitudinal data suggest  $P_{CO_2}$  levels <35 mmHg in  $\geq 15$  out of 35 measurements, similar to our observations. To the best of our knowledge, this phenomenon is not described in other neuromuscular diseases.

A possible explanation of this phenomenon is the changed mechanics of respiration due to respiratory muscle weakness in patients with SMA. Tidal volumes are known to decrease over time, leading to a compensatory increase in respiratory rate. The consequential rapid shallow breathing pattern is assumed to minimise breathing effort and to reduce diaphragmatic fatigue and would explain an increased  $P_{CO_2}$  washout [11]. However, in general, rapid shallow breathing is associated with increased dead space ventilation, which primarily results in increased  $P_{CO_2}$  levels. We observed lowered  $P_{CO_2}$  levels long before mechanical ventilation was initiated. Therefore, hyperventilation could also be a specific disease characteristic of SMA.

There is evidence that tissues other than  $\alpha$ -motor neurons are involved in the SMA disease process, including vasculature [6, 12, 13]. Relative hyperventilation may therefore be caused by altered carbon dioxide sensing in brain(stem) or carotid bodies, adding a dimension to the complexity of respiratory care for patients with SMA. Limitations of this study are related to the retrospective nature. Only blood samples taken during routine follow-up were included for analysis, aiming to include clinically stable patients. However, we cannot exclude that higher  $P_{CO_2}$  levels may be explained by intercurrent problems, like respiratory tract infections. We included mainly patients with SMA type 2a (n=30) and 2b (n=22). Data are representative of the recently published longitudinal study on survival and respiratory failure. This study showed that 50% of patients with SMA type 2a (n=75) were dependent on at least nocturnal mechanical ventilation after 17.4 years compared to 14.3% of patients with type 2b (n=51) after 25 years [5].

This observational study highlights the low or low-normal range  $P_{CO_2}$  levels in non-ventilated SMA patients. Increases of  $P_{CO_2}$  to normal levels may be a sign of pending respiratory insufficiency in some patients with SMA.

**Esther S. Veldhoen<sup>1</sup>, Camiel A. Wijngaarde<sup>2</sup>, Laura P. Verweij-van den Oudenrijn<sup>1</sup>, Fay-Lynn Asselman<sup>2</sup>, Roelie M. Wösten-van Asperen<sup>3</sup>, Erik H.J. Hulzebos<sup>4</sup>, Kors van der Ent<sup>5</sup>, Inge Cuppen<sup>2</sup>, Michael A. Gaytant<sup>6</sup>, Ruben P.A. van Eijk<sup>2,7</sup> and W. Ludo van der Pol<sup>2</sup>**

<sup>1</sup>Paediatric Intensive Care Unit and Centre of Home Mechanical Ventilation, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. <sup>2</sup>Dept of Neurology, Brain Centre Rudolf Magnus, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. <sup>3</sup>Paediatric Intensive Care Unit, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands. <sup>4</sup>Child Development and Exercise Centre, Wilhelmina Children's Hospital, University Medical Centre, Utrecht University, Utrecht, The Netherlands. <sup>5</sup>Dept of Paediatric Pulmonology, Wilhelmina Children's Hospital, University Medical Centre Utrecht University, Utrecht, The Netherlands. <sup>6</sup>Centre of Home Mechanical Ventilation, Dept of Pulmonology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. <sup>7</sup>Biostatistics and Research Support, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.

Correspondence: Esther S. Veldhoen, Wilhelmina Children's Hospital, University Medical Centre Utrecht, PO Box 85090, 3508 AB Utrecht, The Netherlands. E-mail: E.S.Veldhoen@umcutrecht.nl

Received: 25 Jan 2020 | Accepted after revision: 25 May 2020

**Acknowledgements:** We thank all patients with spinal muscular atrophy who have been participating in our ongoing study and the Dutch Organisation for Neuromuscular Diseases (Spierziekten Nederland) for their continuing support of our research. We would like to thank K.M.K de Vooght (University Medical Centre Utrecht, Utrecht, The Netherlands), for her contribution to this study.

**Conflict of interest:** E.S. Veldhoen has nothing to disclose. C.A. Wijngaarde has nothing to disclose. L.P. Verweij-van den Oudenrijn has nothing to disclose. F-L. Asselman has nothing to disclose. R.M. Wösten-van Asperen has nothing to disclose. E.H.J. Hulzebos has nothing to disclose. K. van der Ent has nothing to disclose. I. Cuppen has nothing to disclose. M.A. Gaytant has nothing to disclose. R.P.A. van Eijk has nothing to disclose. W.L. van der Pol reports grants from Prinses Beatrix Spierfonds and Stichting Spieren voor Spieren, fees for consultancy from Biogen and Avexis, fees for data monitoring committee work from Novartis, outside the submitted work; and is local PI of industry-sponsored trials (TOPAZ, Scholar Rock and Jewelfish, Roche).

**Support statement:** Our work was supported financially by the Prinses Beatrix Spierfonds (WAR 08-24, 13-07, and 14-26) and Stichting Spieren voor Spieren.

## References

- 1 Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. *Lancet Neurol* 2012; 11: 443–452.

- 2 Mercuri E, Finkel RS, Muntoni F, *et al.* Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. *Neuromuscul Disord* 2018; 28: 103–115.
- 3 Wadman RI, Wijngaarde CA, Stam M, *et al.* Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4. *Eur J Neurol* 2018; 25: 512–518.
- 4 Wadman RI, Stam M, Gijzen M, *et al.* Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0–4. *J Neurol Neurosurg Psychiatry* 2017; 88: 365–367.
- 5 Wijngaarde CA, Stam M, Otto LAM, *et al.* Population-based analysis of survival in spinal muscular atrophy. *Neurology* 2020; 94: e1634–e1644.
- 6 Finkel RS, Mercuri E, Meyer OH, *et al.* Diagnosis and management of spinal muscular atrophy: Part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. *Neuromuscul Disord* 2018; 28: 197–207.
- 7 Wijngaarde CA, Veldhoen ES, van Eijk RPA, *et al.* Natural history of lung function in spinal muscular atrophy. *Orphanet J Rare Dis* 2020; 15: 88.
- 8 Schroth MK. Special considerations in the respiratory management of spinal muscular atrophy. *Pediatrics* 2009; 123: Suppl. 4, S245–S249.
- 9 Sansone VA, Racca F, Ottonello G, *et al.* 1st Italian SMA Family Association Consensus Meeting: management and recommendations for respiratory involvement in spinal muscular atrophy (SMA) types I–III, Rome, Italy, 30–31 January 2015. *Neuromuscul Disord* 2015; 25: 979–989.
- 10 Hull J, Aniapravan R, Chan E, *et al.* British Thoracic Society guideline for respiratory management of children with neuromuscular weakness. *Thorax* 2012; 67: Suppl. 1, i1–i40.
- 11 Khirani S, Colella M, Caldarelli V, *et al.* Longitudinal course of lung function and respiratory muscle strength in spinal muscular atrophy type 2 and 3. *Eur J Paediatr Neurol* 2013; 17: 552–560.
- 12 Hamilton G, Gillingwater TH. Spinal muscular atrophy: going beyond the motor neuron. *Trends Mol Med* 2013; 19: 40–50.
- 13 Nash LA, Burns JK, Chardon JW, *et al.* Spinal muscular atrophy: more than a disease of motor neurons? *Curr Mol Med* 2016; 16: 779–792.

Copyright ©ERS 2020.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.